A Phase 1 interventional study of LY3549492 and Placebo in Healthy and Type 2 Diabetes Mellitus (T2D), sponsored by Eli Lilly and Company. Completed at 4 sites in Japan. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it.
The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 92 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Part A:
With an HbA1c value:
Part B:
Exclusion Criteria:
LY3549492 administered orally
Drug: LY3549492
LY3549492 administered orally
Drug: LY3549492
Placebo administered orally
Drug: Placebo
Placebo administered orally
Drug: Placebo
Administered orally
Administered orally
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Day 1 Through Day 127
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492
PK: AUC of LY3549492
Time frame: Day 1 Through Day 127
PK: Maximum Concentration (Cmax) of LY3549492
PK: Cmax of LY3549492
Time frame: Day 1 Through Day 127
Pharmacodynamic (PD): Part A: Change from Baseline in Hemoglobin A1c (HbA1c)
PD: Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Day 1 Through Day 127
PD: Change from Baseline in Body Weight
PD: Change from Baseline in Body Weight
Time frame: Day 1 Through Day 127
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company